A number of companies are developing eczema treatments that aim to outperform the market's current leader, the blockbuster Dupixent.
Corvus Pharmaceuticals reported updated results Tuesday from an early-stage study of an oral treatment for eczema that has the potential to be more effective than currently approved drugs, including the blockbuster therapy Dupixent.
After eight weeks... [455 chars]